The National Institutes of Health (NIH) issued the plan that calls for little or no modification to the Institutes existing efforts to capture royalties on federally-funded research. In conducting the report, NIH found that only four of the 47 FDA-approved drugs with $500 million per year in sales were partly developed with NIH-funded technologies.